Physician profile
Lori A Sullivan
NPI 1417028697
$12,004.36
in general payments reported to CMS, 2019-2025
65 companies · $2,574 in 2025
The $2,574 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,554 · 2020: $925 · 2021: $710 · 2022: $1,573 · 2023: $2,335 · 2024: $2,332 · 2025: $2,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,141 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,141.32 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,739.96 | 2019-2025 | Ubrelvy, Vraylar, Linzess |
| Astrazeneca Pharmaceuticals Lp | $1,261.20 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,070.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,018.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $941.44 | 2019-2025 | |
| Amgen INC. | $613.77 | 2019-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $485.01 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $386.49 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Novartis Pharmaceuticals Corporation | $324.14 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $314.20 | 2020-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $248.82 | 2022-2025 | Qelbree, Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.84 | 2019-2025 | Xifaxan, Cycloset, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.61 | 2019-2024 | Jardiance, Tradjenta |
| E.R. Squibb & Sons, L.L.C. | $190.86 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $167.19 | 2022-2025 | Freestyle Libre 3 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.